Avidity Biosciences, Inc. (RNAM)
Feb 27, 2026 - RNAM was delisted (reason: acquired by NVS)
71.36
0.00 (0.00%)
Inactive · Last trade price on Feb 26, 2026
Avidity Biosciences Revenue
In the year 2025, Avidity Biosciences had annual revenue of $18.76M with 72.11% growth. Avidity Biosciences had revenue of $860.00K in the quarter ending December 31, 2025, a decrease of -71.07%.
Revenue (ttm)
$18.76M
Revenue Growth
+72.11%
P/S Ratio
n/a
Revenue / Employee
$36,703
Employees
511
Market Cap
n/a
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 18.76M | 7.86M | 72.11% |
| Dec 31, 2024 | 10.90M | 1.34M | 13.99% |
| Dec 31, 2023 | 9.56M | 336.00K | 3.64% |
| Dec 31, 2022 | 9.22M | -102.00K | -1.09% |
| Dec 31, 2021 | 9.33M | 2.54M | 37.41% |
| Dec 31, 2020 | 6.79M | 4.47M | 192.67% |
| Dec 31, 2019 | 2.32M | 1.94M | 511.87% |
| Dec 31, 2018 | 379.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRNAM News
- 19 days ago - Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies - PRNewsWire
- 20 days ago - Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - PRNewsWire
- 23 days ago - Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders - PRNewsWire
- 4 weeks ago - The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 - PRNewsWire
- 6 weeks ago - Avidity Biosciences Announces Expected Record Date for Spin-Off - PRNewsWire
- 6 weeks ago - Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance - Seeking Alpha
- 7 weeks ago - Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development - Accesswire
- 2 months ago - Pharma sector doubles down on AI amid hopes of slashing costs, timelines - Reuters